These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 9151898)
1. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. Steven NM; Annels NE; Kumar A; Leese AM; Kurilla MG; Rickinson AB J Exp Med; 1997 May; 185(9):1605-17. PubMed ID: 9151898 [TBL] [Abstract][Full Text] [Related]
2. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows JM; Moss DJ; Misko IS Int Immunol; 1997 Nov; 9(11):1745-55. PubMed ID: 9418135 [TBL] [Abstract][Full Text] [Related]
3. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection. Elliott SL; Pye SJ; Schmidt C; Cross SM; Silins SL; Misko IS J Infect Dis; 1997 Oct; 176(4):1068-72. PubMed ID: 9333169 [TBL] [Abstract][Full Text] [Related]
4. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. Pepperl S; Benninger-Döring G; Modrow S; Wolf H; Jilg W J Virol; 1998 Nov; 72(11):8644-9. PubMed ID: 9765404 [TBL] [Abstract][Full Text] [Related]
5. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. White CA; Cross SM; Kurilla MG; Kerr BM; Schmidt C; Misko IS; Khanna R; Moss DJ Virology; 1996 May; 219(2):489-92. PubMed ID: 8638417 [TBL] [Abstract][Full Text] [Related]
6. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044 [TBL] [Abstract][Full Text] [Related]
7. The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. Fogg MH; Garry D; Awad A; Wang F; Kaur A J Immunol; 2006 Mar; 176(6):3391-401. PubMed ID: 16517707 [TBL] [Abstract][Full Text] [Related]
8. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. Benninger-Döring G; Pepperl S; Deml L; Modrow S; Wolf H; Jilg W Virology; 1999 Nov; 264(2):289-97. PubMed ID: 10562493 [TBL] [Abstract][Full Text] [Related]
9. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. Bogedain C; Wolf H; Modrow S; Stuber G; Jilg W J Virol; 1995 Aug; 69(8):4872-9. PubMed ID: 7609055 [TBL] [Abstract][Full Text] [Related]
10. Absence of Epstein-Barr virus-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis. Enssle KH; Fleischer B Clin Exp Immunol; 1990 Mar; 79(3):409-15. PubMed ID: 1690617 [TBL] [Abstract][Full Text] [Related]
11. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791 [TBL] [Abstract][Full Text] [Related]
13. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567 [TBL] [Abstract][Full Text] [Related]
14. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. Burrows SR; Silins SL; Moss DJ; Khanna R; Misko IS; Argaet VP J Exp Med; 1995 Dec; 182(6):1703-15. PubMed ID: 7500015 [TBL] [Abstract][Full Text] [Related]
15. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Rickinson AB; Moss DJ Annu Rev Immunol; 1997; 15():405-31. PubMed ID: 9143694 [TBL] [Abstract][Full Text] [Related]
16. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Schmidt C; Burrows SR; Sculley TB; Moss DJ; Misko IS Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9478-82. PubMed ID: 1719531 [TBL] [Abstract][Full Text] [Related]
17. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis. Al Tabaa Y; Tuaillon E; Jeziorski E; Ouedraogo DE; Bolloré K; Rubbo PA; Foulongne V; Rodière M; Vendrell JP J Clin Virol; 2011 Sep; 52(1):33-7. PubMed ID: 21684200 [TBL] [Abstract][Full Text] [Related]
18. In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients. Strang G; Rickinson AB Immunology; 1987 Dec; 62(4):647-54. PubMed ID: 2828228 [TBL] [Abstract][Full Text] [Related]
19. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. Steven NM; Leese AM; Annels NE; Lee SP; Rickinson AB J Exp Med; 1996 Nov; 184(5):1801-13. PubMed ID: 8920868 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]